It didn't take long for the SpaceX (SPCX) IPO frenzy to die down...

On June 12, public trading opened on SpaceX shares for $135 a share. It was the most anticipated and valuable IPO of all time. The first few days didn't disappoint. Elon Musk became the world's first trillionaire as shares soared to $225.

But as I write, shares trade for around $118. That's 12.6% below the IPO price.

It's not unusual to see a reversal on a big IPO. I've been telling readers that SpaceX is overhyped and that the company's $2.7 trillion peak valuation wasn't justified for a company that lost about $5 billion last year.

But SpaceX has also had some technical difficulties this month...

Last week, it aborted a Starship flight test seconds before its launch due to engine issues. (Starship is the vehicle SpaceX hopes will take people to Mars.) Then, on Monday, SpaceX scrubbed the launch of its Falcon 9 rocket, which was meant to take 24 satellites into space. The company didn't give its reasons, but it did launch successfully the next day.

Some investors see these troubles as a reason to stay away. Others argue that, at its core, SpaceX isn't a space-exploration company – it's an AI one. So who cares about a scrubbed mission or two? And to me, this is a dud investment because of its inflated valuation.

The real lesson here is that the real winners of the SpaceX IPO were never going to be average shareholders, but those who got in before the company went public – like employees and accredited investors.

The trouble is that most folks don't have a chance to get in on the ground floor of these companies...

But there's another great opportunity to see big gains outside of a company's IPO. It involves an asset that I've personally invested in and achieved stellar results with. For a certain group of folks, every $10,000 turned into $175,000.

And right now, the AI boom is fueling major investment in this asset.

Next week, my colleague Luke Lango (from our corporate affiliate InvestorPlace) is hosting the 2026 AI Megadeal Event, where he'll reveal:

  • Why Silicon Valley insiders are in an all-out race to secure their positions in a little-known AI asset that does not trade on the stock market...
  • How to get your cut of the $8.9 trillion windfall swirling around this asset in the next 12 to 24 months...
  • Why this asset was an instrumental stepping stone to Luke becoming a millionaire by age 26, as well as what made Elon Musk and Mark Cuban rich in their early days...

Plus, you'll get Luke's live recommendation for this particular asset. It's free for all day-of attendees.

Luke is the best kind of analyst to bring this kind of research to you. No one else I know has the same combination of expertise, insight, and Silicon Valley connections.

Click here to reserve your spot.

Now, let's get to this week's Q&A... And as always, keep sending your comments, questions, and topic suggestions to feedback@healthandwealthbulletin.com. My team and I read every e-mail.

The Right Way to Wash Produce 

Q: Doc, thanks for your issue on cyclosporiasis. Do you have any tips for washing produce? – S.M.

A: Thanks for your question, S.M. The rinse I prefer for produce is a mix of water and white vinegar (about 3 to 4 parts water to 1 part vinegar). I let everything soak for a few minutes and then rinse the fruits and vegetables with just water.

If you're short on time, at the very least, even a simple run under the tap helps... A study from the Journal of Food Protection also showed that simply letting leafy greens soak in cold tap water for two minutes before rinsing had a similar effect to a long soak.

But for irregularly shaped foods with lots of tight spaces, like broccoli, you might want to take the time to give them a good soak.

That's my standard everyday advice for washing produce. But you should know this won't reduce your risk of getting the cyclosporiasis parasite. As I mentioned on Tuesday, stick with produce that you can cook or peel until we learn the culprit.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
July 24, 2026

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top